A new early phase study at UCLA's Jonsson Cancer Center for the first time pairs two molecularly targeted drugs as a one-two punch to fight metastatic breast cancer. The drugs attack only the cancer and the blood vessel cells and leave the healthy cells unharmed.

Jonsson Cancer Center researchers are seeking volunteers with untreated HER-2/neu positive advanced breast cancer to participate in the research which does not use chemotherapy or other conventional treatments. The study combines the monoclonal antibody Herceptin with the experimental angiogenesis inhibitor Avastin which current studies indicate may extend the lives of patients with advanced colorectal cancer.

For more information contact UCLA at 310-825-8375